JP2016527202A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527202A5
JP2016527202A5 JP2016519586A JP2016519586A JP2016527202A5 JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5 JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5
Authority
JP
Japan
Prior art keywords
amount
compound
cancer
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041643 external-priority patent/WO2014200969A2/en
Publication of JP2016527202A publication Critical patent/JP2016527202A/ja
Publication of JP2016527202A5 publication Critical patent/JP2016527202A5/ja
Pending legal-status Critical Current

Links

JP2016519586A 2013-06-10 2014-06-10 癌の治療方法 Pending JP2016527202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833186P 2013-06-10 2013-06-10
US61/833,186 2013-06-10
PCT/US2014/041643 WO2014200969A2 (en) 2013-06-10 2014-06-10 Methods of treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016527202A JP2016527202A (ja) 2016-09-08
JP2016527202A5 true JP2016527202A5 (enExample) 2017-07-20

Family

ID=52022914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519586A Pending JP2016527202A (ja) 2013-06-10 2014-06-10 癌の治療方法

Country Status (4)

Country Link
US (1) US20170035917A1 (enExample)
EP (1) EP3008212A4 (enExample)
JP (1) JP2016527202A (enExample)
WO (1) WO2014200969A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3046566B1 (en) 2013-09-19 2020-12-02 The Research Foundation for The State University of New York Methods and materials for treating liver steatosis
AU2016243512A1 (en) * 2015-03-27 2017-11-09 The Research Foundation For The State University Of New York Methods and materials for treating cancer
EP3273972A4 (en) 2015-03-27 2018-10-31 The Research Foundation for The State University of New York Methods and materials for reducing amyloid beta levels within a mammal
US12287389B1 (en) * 2015-07-31 2025-04-29 Fonar Corporation Method and system for monitoring effectiveness of a treatment regimen
IL324632A (en) 2016-12-01 2026-01-01 Regeneron Pharma Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
WO2019213024A1 (en) * 2018-04-30 2019-11-07 Integral Molecular, Inc. Glucose transporter 4 antibodies, methods of making the same, and uses thereof
CN109053782B (zh) * 2018-08-09 2020-01-17 潍坊博创国际生物医药研究院 多功能靶向免疫小分子抗癌药枸橼酸Bestazomib及其制备方法与应用
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052080A1 (en) * 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
HRP20150592T4 (hr) * 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
RU2013112156A (ru) * 2010-09-21 2014-10-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Аналоги холина в качестве радиоактивного индикатора
CA2820384A1 (en) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2013028907A1 (en) * 2011-08-23 2013-02-28 Infinity Pharmaceuticals, Inc. Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof
EP2753334B1 (en) * 2011-08-30 2022-10-19 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
CA2855356A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors

Similar Documents

Publication Publication Date Title
US11707539B2 (en) FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
US11730736B2 (en) Anticancer agents
JP2014510728A5 (enExample)
JP7169297B2 (ja) 再発膠芽腫（ｒｇｂｍ）の治療方法
RU2762193C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
JP2015536964A5 (enExample)
JP2010270124A5 (enExample)
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
JP2015212268A5 (enExample)
JP2014513089A5 (enExample)
JP2012255026A5 (enExample)
JP2011529968A5 (enExample)
JP2015522033A5 (enExample)
MX2013013014A (es) Metodo para el tratamiento de tumores solidos avanzados.
JP2014512355A5 (enExample)
CN105452258A (zh) 使用双核金(i)化合物用于癌症治疗的方法
JP2019530706A5 (enExample)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2018531605A5 (enExample)
JP2014530181A5 (enExample)
TW201141472A (en) Method to treat small cell lung cancer
JP7568309B2 (ja) 癌を処置する方法
JP2015515974A5 (enExample)
TWI856060B (zh) 口服二氧戊環核苷酸與抗pd1或抗pdl1單株抗體併用治療肝癌之方法
CN105616411A (zh) 治疗结肠癌的组合物及其应用